

Date: July 28, 2025

**BSE Limited**

Corporate Relationship Dept.,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001

**Scrip Code: 532039**

**Sub: Zenotech Laboratories Limited - Outcome of the Board Meeting held today, i.e., July 28, 2025**

---

Further to the communication dated July 19, 2025, pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) this is to inform that the Meeting of the Board of Directors of the Company (“Board”) was held today, i.e., July 28, 2025, which commenced at 3:30 P.M. and concluded at 6:40 P.M., IST. The Board has, *inter-alia*:

**1. Approved Unaudited Standalone Financial Results**

The Unaudited Standalone Financial Results for the quarter ended June 30, 2025, as approved pursuant to Regulation 33 of the Listing Regulations, along with the Limited Review Report of the Statutory Auditors, are annexed herewith as **Annexure A**.

**2. Approved the appointment of M/s. G S K A & Co., as the Statutory Auditors of the Company**

M/s. G S K A & Co., (Firm Registration No. 147093W) as the Statutory Auditors of the Company to hold office for a term of 5 consecutive years i.e., from the conclusion of 36<sup>th</sup> Annual General Meeting (AGM) to the conclusion of the 41<sup>st</sup> AGM, subject to the approval of the Shareholders at the ensuing AGM. The requisite details under the Listing Regulations are annexed herewith as **Annexure B**.

### **3. Approved convening 36<sup>th</sup> Annual General Meeting**

The 36<sup>th</sup> Annual General Meeting (“AGM”) of the Company will be held on Friday, September 26, 2025, at 10:30 A.M. IST through Videoconferencing. The Notice of the AGM and the Annual Report will be released in due course.

Shareholders are requested to get their information updated with the depositories (for shares held in demat) or with the Company’s RTA (for shares held in physical form), so that Notice of the AGM and the Annual Report can be received by email.

**For Zenotech Laboratories Limited**

(Abdul Gafoor Mohammad)

**Company Secretary & Compliance Officer**

**ICSI Membership No. A22331**

*Encl: as above*

**Independent Auditor's Review Report on review of Interim Financial Results**

To the Board of Directors of Zenotech Laboratories Limited

1. We have reviewed the unaudited financial results ("the Statement") of **Zenotech Laboratories Limited** ("the Company") for the quarter ended 30<sup>th</sup> June 2025, being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations")

2. **Management's Responsibility**

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

3. **Auditor's Responsibility**

Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



#### 4. Conclusion

Based on our review conducted, as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PKF Sridhar & Santhanam LLP  
Chartered Accountants  
Firm Registration No. 0039905/S200018

*JK VNSS Viswanadh*

Viswanadh VNSS Kuchi  
Partner  
Membership No. 210789  
Place: Hyderabad  
Date: 28-July-2025  
UDIN: 25210789BMOUUU3015



**ZENOTECH LABORATORIES LIMITED**

CIN: L27100TG1989PLC010122

Survey No.250-252, Turkapally (V), Shameerpet (M), Hyderabad - 500078

Phone:+91 90320 44584/585/586 Website: www.zenotechlab.com

Standalone Unaudited Financial Results for the Quarter ended 30 June 2025

(Rs in lakhs, except for EPS)

Sl. No.	Particulars	Quarter ended		Year ended	
		30.06.2025	31.03.2025	30.06.2024	31.03.2025
		Unaudited	Audited*	Unaudited	Audited
I	Revenue From Operations	863.91	1,111.32	889.49	3,897.57
II	Other Operating Income	100.41	101.77	101.77	407.14
III	Other Income	58.84	49.32	33.70	154.86
IV	<b>Total Income (I+II+III)</b>	<b>1,023.16</b>	<b>1,262.41</b>	<b>1,024.96</b>	<b>4,459.57</b>
V	<b>Expenses</b>				
	a). Cost of materials consumed	-	42.75	7.11	84.02
	b). Purchase of Stock-in-Trade	-	-	-	-
	c). Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-
	d). Employee benefit expenses	353.56	323.28	295.40	1,237.78
	e). Finance costs	-	-	-	-
	f). Depreciation and amortization expense	177.37	172.69	172.66	696.01
	g). Other Expenses	364.55	400.14	345.24	1,564.89
	<b>Total expenses</b>	<b>895.48</b>	<b>938.86</b>	<b>820.41</b>	<b>3,582.70</b>
VI	<b>Profit/(Loss) before exceptional items and tax (IV-V)</b>	<b>127.68</b>	<b>323.55</b>	<b>204.55</b>	<b>876.87</b>
VII	Exceptional items	-	(4.88)	-	192.32
VIII	<b>Profit/(Loss) before tax (VI+VII)</b>	<b>127.68</b>	<b>318.67</b>	<b>204.55</b>	<b>1,069.19</b>
IX	<b>Tax expense</b>				
	a). Current Tax	22.21	190.49	-	190.49
	b). Prior Period Tax	-	58.84	-	58.84
	c). Deferred Tax	6.52	(53.64)	75.58	258.57
	<b>Total Tax Expense (IX)</b>	<b>28.72</b>	<b>195.69</b>	<b>75.58</b>	<b>507.90</b>
X	<b>Profit/(Loss) for the period (VIII-IX)</b>	<b>98.96</b>	<b>122.98</b>	<b>128.97</b>	<b>561.29</b>
XI	<b>Other Comprehensive Income</b>				
	a). Items that will not be reclassified to Profit or Loss				
	Re - measurement of the defined benefit obligations	(0.59)	0.51	(0.96)	(2.37)
	b). Items that will be reclassified to Profit or Loss				
	Less: Income Tax	0.17	(0.15)	0.28	0.69
	<b>Total Other Comprehensive Income (a+b)</b>	<b>(0.42)</b>	<b>0.36</b>	<b>(0.68)</b>	<b>(1.68)</b>
XII	<b>Total Comprehensive Income for the period (X+XI)</b>	<b>98.54</b>	<b>123.34</b>	<b>128.29</b>	<b>559.61</b>
XIII	<b>Paid-up equity share capital (Face value of ₹ 10/- per share)</b>	<b>6,103.06</b>	<b>6,103.06</b>	<b>6,103.06</b>	<b>6,103.06</b>
XIV	<b>Reserves i.e. Other equity</b>				<b>3,510.02</b>
XV	<b>Earnings/ (loss) per share (of ₹ 10/- each) (not annualised)</b>				
	a) Basic	0.16	0.20	0.21	0.92
	b) Diluted	0.16	0.20	0.21	0.92

\* The figures for the quarter ended March 31, 2025 are the balancing figure between the audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter of the relevant financial year which were subject to limited review by the Statutory Auditor of the Company.

See accompanying notes to the financial results



**Notes:**

1. The above financial results for the quarter ended June 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 28<sup>th</sup> July, 2025 and have undergone a 'limited review' by the Statutory Auditors of the Company.
2. These financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India.
3. Majority of the matters relating to several financial and non-financial irregularities pertaining to period prior to November 12, 2011 were abated/settled. Accordingly, based on the steps taken by the Company and evidence available so far, the Company believes that the financial impact if any, with respect to those legacy matters on the results of the Company is not material.
4. The Company's overseas subsidiaries namely Zenotech Farmaceutica Do Brasil Ltda (Zenotech-Brazil) and Zenotech Inc (Zenotech-USA) were defunct and reported as cancelled/revoked respectively based on the Registration Cancellation certificate dated 8th June 2022 and Long Form Standing certificate dated 15th June 2022 respectively, received from the concerned authorities. Winding up order for Zenotech Laboratories Nigeria Limited has been received during FY: 2019-20. However, related filings with RBI are pending. Accordingly, the Company is of the view that it does not have subsidiaries, joint ventures and associates within the definition of Ind AS 110 and hence consolidated financial statements/Results are no longer applicable.
5. Other operating income relates to rentals for the Biotech facility and equipment leased to Sun Pharmaceutical Industries Limited for R&D activities.
6. The Company has only one segment, i.e. Pharmaceuticals.
7. The Company has registered under Amnesty Scheme during the quarter ended 31st March 2024 and request filed for Export Obligation Discharge Certificate (EODC) with DGFT online. Out of the 14 licenses approved under the scheme, 12 licenses were settled in the previous year. Accordingly, the Company provided reversal amounting to ₹192.32 lakhs for the year ended 31st March 2025. This reversal, following the crystallization of liability, has been reported as an Exceptional Item during the previous year / quarters. As of 30th June 2025, the balance provision amounts to ₹422.10 lakhs (31st March 2025 ₹422.10 lakhs).
8. Figures for previous period/ year have been regrouped to conform to the current period presentation.

By Order of the Board



Chairman of the Board meeting  
DIN: 01219312

Place: New Delhi  
Date: 28-July-2025

**ANNEXURE B**

**Information as required under Regulation 30 - Part A of Para A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015**

<b>S. No.</b>	<b>Particulars</b>	<b>Description</b>
<b>1.</b>	<b>Reason for change</b>	<p>M/s. PKF Sridhar &amp; Santhanam LLP, will complete their two consecutive terms as Statutory Auditors of the Company on conclusion of the ensuing 36<sup>th</sup> AGM.</p> <p>Therefore, the Board of Directors of the Company considering the experience and expertise and based on the recommendation of the Audit Committee, had appointed M/s. G S K A &amp; Co., (Firm Registration No. 147093W) as the Statutory Auditors of the Company to hold office for a term of 5 consecutive years i.e., from the conclusion of 36<sup>th</sup> Annual General Meeting to the conclusion of 41<sup>st</sup> Annual General Meeting, subject to approval of the Shareholders at the ensuing AGM.</p>
<b>2.</b>	<b>Date of appointment/<del>cessation</del> &amp; term of appointment</b>	Please refer Response to Point (1) above.
<b>3.</b>	<b>Brief Profile</b>	M/s. G S K A & Co., is a firm of Chartered Accountants registered and empaneled with the Institute of Chartered Accountants of India. It was established in the year 2018. It has its registered office at 4th Floor, Red Building, Above Shinhan Bank, Boat Club Road, Pune - 411 001. It is primarily engaged in providing audit and assurance services to its clients.
<b>4.</b>	<b>Disclosure of relationships between directors</b>	Not applicable